Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Total Debt (2016 - 2025)

Historic Total Debt for Abvc Biopharma (ABVC) over the last 12 years, with Q3 2025 value amounting to $809103.0.

  • Abvc Biopharma's Total Debt fell 972.35% to $809103.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $809103.0, marking a year-over-year decrease of 972.35%. This contributed to the annual value of $840252.0 for FY2024, which is 656.08% down from last year.
  • According to the latest figures from Q3 2025, Abvc Biopharma's Total Debt is $809103.0, which was down 972.35% from $871951.0 recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's Total Debt ranged from a high of $2.0 million in Q2 2021 and a low of $402436.0 during Q3 2021
  • Over the past 5 years, Abvc Biopharma's median Total Debt value was $852500.0 (recorded in 2023), while the average stood at $956366.8.
  • Data for Abvc Biopharma's Total Debt shows a peak YoY increase of 20238.97% (in 2021) and a maximum YoY decrease of 8203.1% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Abvc Biopharma's Total Debt stood at $1.0 million in 2021, then soared by 81.49% to $1.9 million in 2022, then crashed by 52.51% to $899250.0 in 2023, then fell by 6.56% to $840252.0 in 2024, then fell by 3.71% to $809103.0 in 2025.
  • Its last three reported values are $809103.0 in Q3 2025, $871951.0 for Q2 2025, and $801407.0 during Q1 2025.